期刊文献+

TGF-β1-509C/T基因多态性与不同中医证型原发性膝骨关节炎的关系 被引量:11

Association of TGF-β1-509C/T polymorphisms with Common Traditional Chinese medicine Syndromes primary knee osteoarthritis
下载PDF
导出
摘要 目的探讨TGF-β1-509C/T基因多态性与不同中医证型原发性膝骨关节炎(primary knee osteoarthritis,PKOA)遗传易感性的关系。方法采用关联分析,严格按照病例纳入标准,随机选取湖南地区PKOA患者88例(瘀血阻滞组52例,肾虚亏髓组36例),应用聚合酶链式反应-限制性片段长度多态性分析(PCR-RFLP)对所选对象TGF-β1-509位点基因和基因型进行检测。结果瘀血阻滞型PKOA组携带CC基因型的频率明显要高于对照组(50.0%vs 13.5%;χ~2=15.996,P〈0.05),差异有统计学意义;Logistic回归分析结果显示,与TGF-β1-509位点TT基因型相比,携带TGF-β1-509位点CC基因型有患瘀血阻滞型PKOA风险(OR=9.75,95%CI=7.10-13.46))。结论 TGF-β1-509位点与瘀血阻滞型PKOA相关,CC基因型是瘀血阻滞型PKOA易感基因型。 Objective To probe association of the promoter -509C/T gene polymorphisms of transforming growth factor-β1 (TGF-β1) with Common raditional Chinese medicine Syndromes primary knee osteoarthritis (PKOA). Methods the promoter - 509C/T gene polymorphisms were analysised by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) in 88 patients with primary knee osteoarthritis (qi stagnation and blood stasis syndrome 52,Kidney empty marrow deficient syndrome36) from Affiliated Hospital to Hunan Insititute Chinese Medicine. Results Blood stasis type PH group carrying CC genotype frequency is significantly higher than the control(50.0% vs 13.5%;χ^2=15.996 ,P〈0.05),the difference was statistically significant; Logistic regression analysis showed that the TGF compared -β1-509 sites TF genotype,TGF-β1-509 locus genotype CC suffering from qi stagnation and blood stasis syndrome PKOA risk (OR=9.75,95%CI=7.10-13.46). Conclusion the promoter - 509C/T gene polymorphisms of transforming growth factor-β1 is associated with the PKOA patients. The CC genotype may be qi stagnation and blood stasis syndrome risk genotype.
作者 罗洁 许辉
出处 《江西医药》 CAS 2016年第2期134-136,共3页 Jiangxi Medical Journal
基金 湖南省科技厅课题(项目编号:2013FJ3152) 湖南省中医药研究院院级课题(编号:201224)
关键词 原发性膝骨关节炎 中医证型 转化生长因子Β1 基因多态性 聚合酶链式反应-限制性片段长度多态性 Primary knee osteoarthritis (PKOA) Common TCM Syndromes Transforming growth factor beta 1 (TGF-131) Genetic polymorphism Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP)
  • 相关文献

参考文献5

二级参考文献42

  • 1.中华人民共和国中医药行业标准·中医病证诊断疗效标准[S].[S].国家中医药管理局,1994.30-31.
  • 2Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum, 2000, 43: 1905-1915.
  • 3Schnitzer TJ, American College of Rheumatology. Update of ACR guidelines for osteoarthritis: role of the coxibs. J Pain Symptom Manage, 2002, 23(4 Suppl): S24-34.
  • 4Hochberg MC, Ahman RD, Brandt KD, et al. Guidelines for the medical management of osteoarthritis. Part Ⅱ. Osteoarthritis of the knee. American College of Rheumatology. Arthritis Rheum, 1995, 38:1541-1546.
  • 5Hochberg MC, Ahman RD, Brandt KD, et al. Guidelines for the medical management of osteoarthritis. Part Ⅰ. Osteoarthritis of the hip. American College of Rheumatology. Arthritis Rheum, 1995, 38: 1535-1540.
  • 6Simon LS, Lipman AG, Jacox AK, eds. Pain in osteoarthritis, rheumatoid arthritis and juvenile chronic arthritis. 2nd ed. Glenview (IL): American Pain Society (APS), 2002. 179.
  • 7Zhang W, Doherty M, Leeb BF, et al. EULAR evidence based recommendations for the management of hand osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis, 2007, 66: 377-388.
  • 8Zhang W, Doherty M. EULAR recommendations for knee and hip osteoarthritis: a critique of the methodology. Br J Sports Med, 2006, 40: 664-669.
  • 9Pendleton A, Arden N, Dougados M, et al. EULAR recommendations for the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis, 2000, 59: 936-944.
  • 10Zhang W, Doherty M, Arden N, et al. EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis, 2005, 64: 669-681.

共引文献1975

同被引文献117

引证文献11

二级引证文献62

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部